PB1046 & PB1120

Roof SR et al. 2015. Chronic treatment with PB1046, a stable and long-acting vasoactive intestinal peptide receptor agonist, improves cardiac and skeletal muscle function in mouse models of Duchenne Muscular Dystrophy. Poster presentation at the American Academy of Neurology Annual Meeting 2015.

del Rio CL et al. 2014a. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, Improves Arterial Elastance and Ventriculo-Arterial Coupling: Effects in Rats with Induced Diastolic Dysfunction via Renoprival Hypertension. Poster presentation at the American Heart Association High Blood Pressure Research 2014 Scientific Session.

del Rio CL et al. 2014b. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist: Improved Ventriculo-Arterial Coupling and Decreased Myocardial Demand in Sheep with Induced Ischemic Heart Failure. Poster presentation at the ASFA Annual Meeting.

Free A et al. 2014. A Phase 1, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety/Tolerability, Pharmacokinetic and Hemodynamic Response Following Single Ascending Subcutaneous Doses of PB1046 (Vasomera™) in Subjects with Essential Hypertension. Poster presentation at the American Heart Association Scientific Session 2014.

Chappe F et al. 2014. VIP-ELP Fusion Molecules PB1120 and PB1046 Correct F508del-CFTR Dysfunction. Poster presentation at the North American Cystic Fibrosis Conference 2014.

del Rio CL et al. 2013. Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist. Enhanced Contractility and Decreased Myocardial Demand in Dogs with both Normal Hearts and with Pacing-Induced Dilated Cardiomyopathy. Poster presentation at American College of Cardiology 62nd Annual Scientific Session.

Youngblood B et al. 2012. Vasomera™, A Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist. Evidence for Chronic Cardio-Protection in Rats with Doxorubicin-Induced Cardiomyopathy. Poster presentation at Heart Failure Society of America 16th Annual Scientific Meeting.

Yeh ST et al. 2012. Novel Vasoactive Intestinal Peptide-ELP Fusion Protein VPAC-Agonists. Induced Sustained Pulmonary Artery Vaso-Relaxation in Rats with Acute Hypoxia-Induced Pulmonary Hypertension. Poster presentation at American Heart Association High Blood Pressure Research 2012 Scientific Session.

del Rio CL et al. 2011. Evaluation of Vasomera™, A Novel VPAC2-selective VIP Agonist, on Telemetered SHR Rats: Evidence for Dose-dependent Sustained Blood Pressure Control Independent of β-AR Function. Poster presentation at American Heart Association Annual Meeting 2011.

PB1023

Christiansen et al. 2012. Weekly Subcutaneous Doses of (PB1023) a Novel GLP-1 Analogue Reduce Glucose Exposure Dose Dependently. Poster presentation at American Diabetes Association Annual Meeting 2012.

Matson et al. 2011. (PB1023) a Novel GLP-1 Analogue Dose Dependently Reduces Meal Challenge Induced Glucose Exposure Following a Single Subcutaneous Dose. Poster presentation at the Annual Diabetes Technology Meeting 2011.